ImmunityBio Inc. (NASDAQ:IBRX) does about 1.60M shares in volume on a normal day but saw 2536609 shares change hands in Monday trading. The company now has a market cap of 1.81B USD. Its current market price is $4.60, marking a decrease of -0.22% compared to the previous close of $4.61. The 52 week high reached by this stock is $7.85 whilst the lowest price level in 52 weeks is $2.60. The script in recent trading has seen the stock touch a high of $4.75 and a low of $4.21.
ImmunityBio Inc. (IBRX) has a 20-day trading average at $4.73 and the current price is -41.40% off the 52-week high compared with 76.92% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.37 and its 200-day simple moving average is $4.66. If we look at the stock’s price movements over the week, volatility stands at 7.53%, which increases to 8.15% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 41.72 to suggest the stock is neutral.
2 analysts observing the ImmunityBio Inc. (IBRX) stock have set the 12-month price targets for the company’s shares at between $8.00 and $10.00. The consensus objective for the share price is $9.00, suggesting that the stock has a potential upside of 48.89% over the period. The median price target is 48.89% away from the current levels at $9.00.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 03, 2022 when Jefferies initiated the stock to “Buy” and issued a price target of $8.
The current price level is -3.96%, -14.38%, and -1.48% away from its SMA20, SMA50, and SMA200 respectively, with the IBRX price moving above the 50-day SMA on January 23. ImmunityBio Inc. (IBRX) stock is down -3.77% over the week and -20.55% over the past month. Its price is -9.27% year-to-date and -18.29% over the past year.
The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.23 and -$0.86 for whole year. IBRX’s earnings per share are forecast to grow by 3.40% this year and -1.20% over next year. Expected sales for next quarter are $20k, which analysts say will come at $250k for the current fiscal year and next year at $11.4 million. In addition, estimates put the company’s current quarterly revenue at an average of $20k.
Its 12-month price target is $9.00. To reach the target analysts have set, the stock logically needs to grow 48.89 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $8.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $10.00.
Outstanding shares total 400.06M with insiders holding 79.16% of the shares and institutional holders owning 8.70% of the company’s common stock. The company has a return on investment of -90.10% and return on equity of 112.20%. The beta has a value of 1.48. Price to sales ratio is 3009.09.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in ImmunityBio Inc. (IBRX) to 4,626,567 shares, mirroring a recent increase by 0.41%. SPDR S&P Biotech ETF added 18704.0 shares of ImmunityBio Inc. common stock bringing its total worth to about $23.46 million at the end of recent close, SEC documents show. Vanguard Small Cap Index Fund cut their holdings by -0.41% in the company over the course of the most recent quarter. It now holds a 0.50% position in ImmunityBio Inc. thanks to 2.06 million shares amounting to $10.46 million.